BEAM

Over the past six months (April 2026 - October 2026), Beam Therapeutics' stock experienced several notable events. In February 2026, the stock rose 5.37% following Q4 2025 results and securing $500 million in non-dilutive financing, extending its cash runway. March 2026 saw positive investor sentiment due to encouraging early data from a Phase I/II study of BEAM-302 for AATD. By June 2026, shares had risen 21% over three months, driven by positive clinical developments and rapid regulatory progress. On August 4, 2026, the stock saw a +9.42% change. However, on September 8, 2026, the stock price decreased by 9.54% after Beam presented updated clinical data for BEAM-302 at the European Respiratory Society (ERS) Congress. In September 2026, news of investor alerts and fraud investigations by law firms emerged. On October 2, 2026, Beam Therapeutics' treasurer sold 187 shares to cover taxes. Overall, the stock lost 7.8% over the past 12 months but increased by 5.46% in the past month leading up to October 10, 2026.